UY37936A - AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 - Google Patents

AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1

Info

Publication number
UY37936A
UY37936A UY0001037936A UY37936A UY37936A UY 37936 A UY37936 A UY 37936A UY 0001037936 A UY0001037936 A UY 0001037936A UY 37936 A UY37936 A UY 37936A UY 37936 A UY37936 A UY 37936A
Authority
UY
Uruguay
Prior art keywords
agents
expression
inhibit
compositions
asgr1
Prior art date
Application number
UY0001037936A
Other languages
English (en)
Inventor
Stacey Melquist
Tao Pei
Zhen Li
D Given Bruce
Rui Zhu
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of UY37936A publication Critical patent/UY37936A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente memoria da a conocer composiciones y métodos para la inhibición de la expresión génica del receptor de asialoglicoproteína 1 (ASGR1). Se dan a conocer agentes de interferencia de ARN (iARN), por ejemplo, agentes iARN de doble hebra, y conjugados agente iARN-ligando dirigido a la diana para inhibir la expresión de un gen ASGR1. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN ASGR1, opcionalmente con uno o más agentes terapéuticos adicionales.
UY0001037936A 2017-10-17 2018-10-17 AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 UY37936A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573206P 2017-10-17 2017-10-17
US201762608606P 2017-12-21 2017-12-21
US201862635277P 2018-02-26 2018-02-26

Publications (1)

Publication Number Publication Date
UY37936A true UY37936A (es) 2019-05-31

Family

ID=66173364

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037936A UY37936A (es) 2017-10-17 2018-10-17 AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1

Country Status (9)

Country Link
US (1) US11492624B2 (es)
EP (1) EP3697909A4 (es)
JP (1) JP7473472B2 (es)
CN (1) CN111212909A (es)
AU (1) AU2018352379A1 (es)
CA (1) CA3079413A1 (es)
TW (1) TW201918555A (es)
UY (1) UY37936A (es)
WO (1) WO2019079294A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230115344A (ko) * 2016-09-02 2023-08-02 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
CN116617390A (zh) * 2022-02-11 2023-08-22 武汉大学 Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
WO2024046297A1 (zh) * 2022-09-02 2024-03-07 北京福元医药股份有限公司 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
MXPA01009073A (es) 1999-03-10 2002-05-06 Phogen Ltd Suministro de acidos nucleicos y proteinas a las celulas.
CN1300312C (zh) * 2004-08-23 2007-02-14 中国人民解放军军事医学科学院放射与辐射医学研究所 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
EP2087110A2 (en) * 2006-10-11 2009-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
ES2562817T3 (es) 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US8932572B2 (en) 2011-08-26 2015-01-13 Arrowhead Madison Inc. Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
JP2018535655A (ja) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
KR20230048446A (ko) 2016-03-07 2023-04-11 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
KR20230115344A (ko) * 2016-09-02 2023-08-02 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드

Also Published As

Publication number Publication date
EP3697909A4 (en) 2021-10-13
JP2020537653A (ja) 2020-12-24
US20200283777A1 (en) 2020-09-10
CA3079413A1 (en) 2019-04-25
CN111212909A (zh) 2020-05-29
AU2018352379A1 (en) 2020-06-04
WO2019079294A1 (en) 2019-04-25
TW201918555A (zh) 2019-05-16
JP7473472B2 (ja) 2024-04-23
US11492624B2 (en) 2022-11-08
EP3697909A1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
PH12019502333A1 (en) Targeted compositions
CY1123289T1 (el) Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
CR20190294A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
BR112018008746A8 (pt) composições e métodos para a inibição de atividade de arginase
BR112018010216A2 (pt) purinonas como inibidores da protease específica da ubiquitina 1
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
CO2020015314A2 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso
PH12020550833A1 (en) Rnai constructs for inhibiting pnpla3 expression
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
UY37936A (es) AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1
MX2019002271A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
GEP20217318B (en) Pyrazole magl inhibitors
MX2021014465A (es) Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas.
PH12020550244A1 (en) Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
MX2021006784A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos.
EP4219715A3 (en) Stabilized cebpa sarna compositions and methods of use
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201203